ROP and ATRP fabricated redox sensitive micelles based on PCL-SS-PMAA diblock copolymers to co-deliver PTX and CDDP for lung cancer therapy

Lo, Yu‐Lun; Huang, Xuejun; Chen, Hsuan-Ying; Huang, Yuan-Chun; Liao, Zi-Xian; Wang, Lifang

doi:10.1016/j.colsurfb.2020.111443

Cited by 23 publications

(13 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that these NPs can maintain their integrity until exposed to the TME, incurring selective drug release. Cell apoptosis studies also revealed that treatment of NCI-H520 LC cells with the dual loaded PTX/CIS cross-linked micelles resulted in a 1.77-fold increase in cell death compared to the free drugs [35]. Similarly, redox-responsive manganese dioxide NPs (MnO2 NPs) stabilized with biocompatible polymers polyvinylpyrrolidone (PVP) and polyacrylic acid (PAA) were synthesized and analyzed using magnetic resonance (MR) imaging and measurement of cytotoxic activity on gefitinib-resistant LC cell lines.…”

Section: Figure 1 Representation Of Cellular Components Of Tme In Lcmentioning

confidence: 96%

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Haider¹,

Sherbeny²,

Pittalà³

et al. 2022

Preprint

View full text Add to dashboard Cite

Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer; presents novel nanomedicine therapeutics aimed to improve the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for clinical application of nanomedicine in management of LC resistance.

show abstract

Section: Figure 1 Representation Of Cellular Components Of Tme In Lcmentioning

confidence: 96%

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Haider¹,

Sherbeny²,

Pittalà³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In a study by Yu-Lun Lo et al, a pH/redox-responsive micelle based on a poly(εcaprolactone)-SS-poly (methacrylic acid) (PCL-SS-PMAA) diblock copolymer was fabricated for the dual drug delivery of paclitaxel (PTX) and cisplatin (CIS) [38]. The NPs were intended to utilize the acidic/ROS-rich TME for selective release of the chemotherapeutic agents while enhancing their intracellular accumulation.…”

Section: Tumor Microenvironmentmentioning

confidence: 99%

“…This suggests that these NPs can maintain their integrity until exposed to the TME, incurring selective drug release. Cell apoptosis studies also revealed that treatment of NCI-H520 LC cells with the dual loaded PTX/CIS cross-linked micelles resulted in a 1.77-fold increase in cell death compared to the free drugs [38]. Similarly, redoxresponsive manganese dioxide NPs (MnO2 NPs) stabilized with biocompatible polymers polyvinylpyrrolidone (PVP) and polyacrylic acid (PAA) were synthesized and analyzed using magnetic resonance (MR) imaging and measurement of cytotoxic activity on gefitinibresistant LC cell lines.…”

Section: Tumor Microenvironmentmentioning

confidence: 99%

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Haider

Elsherbeny

Pittalà

et al. 2022

IJMS

View full text Add to dashboard Cite

Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge, as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and the encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer, presents novel nanomedicine therapeutics aimed at improving the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for the clinical application of nanomedicine in the management of LC resistance.

show abstract

“…The cationic polyelectrolytes with amine groups, including PEG-poly(β-amino esters)-poly lactic acid (PLA), PEG-poly(2-(diisopropylamino) ethyl methacrylate), 1,2-distearoyl- sn -glycero-3-phosphoethanolamine- N -[methoxy(polyethylene glycol)] conjugated poly(β-amino esters), PEG-poly(2-(diisopropylamino) ethyl methacrylate-co-dithiomaleimide), PEG-poly(2-(dibutylamino) ethyl methacrylate-co-dithiomaleimide), and poly(N-vinylpyrrolidone)-poly(4-vinylpyridine) [ 104 , 105 , 106 , 107 , 108 ], can protonate under acidic conditions showing hydrophilicity, while they can deprotonate under basic conditions, indicating hydrophobicity ( − NR 2 ↔ NR 3 + ). In contrast, anionic polyelectrolytes with –COOH, such as poly(N-isopropylacrylamide-co-acrylic acid), PCL-SS-poly(methacrylic acid), CTS-poly(methacrylic acid-co-N-isopropylacrylamide), poly( N -(4-methacrylamido)- N -(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide-co- N , N ′-dimethylacrylamide) [ 109 , 110 , 111 , 112 ], can deprotonate and protonate in the opposite manner. For example, imidazole groups with a pair of electrons on the unsaturated nitrogen atom can be easily protonated in slightly acidic environments, resulting in conversion from hydrophobic to hydrophilic [ 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 ].…”

Section: Ph-responsive Nanovehiclesmentioning

confidence: 99%

Recent Advances in pH- or/and Photo-Responsive Nanovehicles

et al. 2021

View full text Add to dashboard Cite

The combination of nanotechnology and chemotherapy has resulted in more effective drug design via the development of nanomaterial-based drug delivery systems (DDSs) for tumor targeting. Stimulus-responsive DDSs in response to internal or external signals can offer precisely controlled delivery of preloaded therapeutics. Among the various DDSs, the photo-triggered system improves the efficacy and safety of treatment through spatiotemporal manipulation of light. Additionally, pH-induced delivery is one of the most widely studied strategies for targeting the acidic micro-environment of solid tumors. Accordingly, in this review, we discuss representative strategies for designing DDSs using light as an exogenous signal or pH as an endogenous trigger.

show abstract

ROP and ATRP fabricated redox sensitive micelles based on PCL-SS-PMAA diblock copolymers to co-deliver PTX and CDDP for lung cancer therapy

Cited by 23 publications

References 61 publications

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Recent Advances in pH- or/and Photo-Responsive Nanovehicles

Contact Info

Product

Resources

About